Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -35.53
- Piotroski Score 1.00
- Grade Buy
- Symbol (TENX)
- Company Tenax Therapeutics, Inc.
- Price $4.50
- Changes Percentage (0.22%)
- Change $0.01
- Day Low $4.46
- Day High $4.68
- Year High $61.20
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/11/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$22.06
- Trailing P/E Ratio -0.16
- Forward P/E Ratio -0.16
- P/E Growth -0.16
- Net Income $-7,710,673
Income Statement
Quarterly
Annual
Latest News of TENX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Citius merges oncology subsidiary with TenX Keane
Citius Pharmaceuticals merged its oncology subsidiary with TenX Keane Acquisition to form Citius Oncology, set to go public on Nasdaq as CTOR. The new company will focus on developing targeted oncolog...
By Yahoo! Finance | 2 months ago
